Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease

International Journal of Laboratory Hematology

Volumn 32, Issue 3, 2010, Pages 320-328

  Pawlus, J ^a   Hotub, M ^a   Kozuch, M ^a   Dabrowska, M ^a   Dobrzyck, S ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Coronary artery disease; Myeloperoxidase; Platelet

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; D DIMER; FIBRINOGEN; MYELOPEROXIDASE; THROMBOCYTE CONCENTRATE; TROPONIN I; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEROXIDASE;

ADULT; AGED; ANALYZER; ARTICLE; ATHEROMA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HEART INFARCTION; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; CYTOLOGY; ENZYMOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; THROMBOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CREATINE KINASE, MB FORM; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PEROXIDASE; PROGNOSIS; TROPONIN I;

EID: 77953552296     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2009.01203.x     Document Type: Article

References (35)

1. Abrams J. (2005) Clinical practice. Chronic stable angina. New England Journal of Medicine 352, 2524-2533.
2. Baldus S., Heeschen C., Meintertz T., Zeiher A., Eiserich J., Münzel T., Simoons M. & Hamm C. (2003) Mye-loperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108, 1440-1445.
3. Baldus S., Heitzer T., Eiserich J.P., Lau D., Mollnau H., Ortak M., Petri S., Gold-mann B., Duchstein H.J., Berger H., Helmchen U., Freeman B.A., Meinertz K.T. & Münzel T. (2004) Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radical Biology and Medicine 37, 902-911.
4. Bell D., Jackson M., Nicoll J.J., Millar A., Dawes J. & Muir A (1990) Inflammatory response neutrophil activation and free radical production after acute myocardial infarction: effect of thrombolytic treatment. British Heart Journal 63, 82-87.
5. Ben-Dor I. & Battler A. (2007) Treatment of stable angina. Heart 93, 868-874.
6. Boos C.J., Balakrishnan B. & Lip G.Y. (2008) MPC-The effect of coronary artery disease severity on time dependent changes in platelet activation indicates in stored whole blood. Journal of Thrombosis and Thrombolysis 25, 135-140.
7. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., Jones R.H., Kereiakes D., Kupersmiyh J., Levin T.N., Pepine C.J., Schaeffer J.W., Smith E.E. III, Steward D.E. & Theroux P. (2002) ACC/AHA 2002 guideline update for the managment of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force Practice Guidelines. Circulation 106, 1893-1900. . org/clinical/guidelines/unstable/unstable. pdf (accessed on 1 October 2002).
8. Brydon L., Magid K. & Steptoe A. (2006) Platelets, coronary heart disease, and stress. Brain, Behavior, and Immunity 20, 113-119.
9. Bugajski P., Kalawski R. & Zurawska J. (1999) Endothelin-1, is involved In plasma mediated stimulation of neutrophil adherence during coronary artery bypass grafting. European Journal of Cardio-Thoracic Surgery 15, 408-412.
10. Danesh J., Collins R., Appleby P. & Peto R. (1998) Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477-1482.
11. Davies M.J., Thomas A.C., Knapman P.A. & Hangartner J.R. (1986) Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 73, 418-427.
12. De Servi S., Mazzone A., Ricevuti G., Mazzucchelli I., Fossati G., Gritt D., Angoli L. & Specchia G. (1995) Clinical and angiographic correlates of leukocyte activation in unstable angina. Journal of the American College of Cardiology 26, 1146-1150.
13. Eiserich J.P., Baldus S., Bernnan M.L., Ma W., Zhang C., Tousson A., Castro L., Lussis A.J., Nauseef W., White R. & Freeman B.A. (2002) Myeloperoxidase a leukocyte-derived vascular NO oxidase. Science 296, 2391-2394.
14. Exner M., Minar E., Melkusch W., Sabeti S., Amighi J., Lalouschek W., Maurer G., Bieglmayer C., Kieweg H., Wagner O. & Shillinger M. (2006) Myeloperoxidase predicts progression of carotid tenosis in states of low high-density lipoprotein cholesterol. Journal of American College of Cardiology 47, 2212-2218.
15. Fu X., Kassim S.Y., Parks W.C. & Heinecke J.W. (2001) Hypochlorous acid oxygenates the cysteine switch domain of promatrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. Journal of Biological Chemistry 276, 41279-41287.
16. Gurm H.S., Bhatt D.L., Gupta R., Ellis S.G., Topol L.J. & Lauer M.S. (2003) Preprocedural white blood count and death after percutaneous coronary intervention. American Heart Journal 146, 692-698.
17. Hamm C. (2000) A classification of unstable angina revisited. Circulation 102, 118-122.
18. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R. & Pepys M.B. (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349, 462-466.
19. Heeschen C., Hamm C.W., Goldman B., Deu A., Langenbrink L. & White H.D. (1999) Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemia syndrome management. Lancet 354, 1757-1762.
20. Hinecke J.W. (2003) Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. American Journal of Cardiology 91, 12A-16A.
21. Klebanoff S.J. (1999) Myeloperoxidase. Proceedings of the Association of American Physicians 111, 383-389
22. Lusis A.J. (2000) Atherosclerosis. Nature 407, 233-241.
23. Malle E., Marsche G., Panzenboeck U. & Sattler W. (2006) Myeloperoxidase-mediated oxidation of highdensity lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Archives of Biochemistry and Biophysics 445, 245-255.
24. Meuwese M.C., Stroes E.S., Hazen S.L., Van Miert J., Kuivenhoven J., Schaub R., Wareham R., Luben R., Kastelein J. & Khaw K. (2007) Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk prospective population study. Journal of the American College of Cardiology 50, 159-165.
25. Naruko T., Ueda M., Haze K., van der Wal A., van der Loos C.M., Itoh A., Komatsu R., Ikura Y., Ogami M., Shimada Y., Ehara S., Yoshiyama M., Takeuchi K., Yoshikawa J. & Becker A.E. (2002) Neutophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106, 2894-2900.
26. Nicholls S.J. & Hazen S.L. (2005) Myelop-eroxidase and Cardiovascular Disease. Atherosclerosis, Thrombosis and Vascular Biology 25, 1102-1111.
27. Nikpoor B., Turecki G., Fournier C., Theroux P. & Rouleau G.A. (2001) A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Candaians. American Heart Journal 142, 336-339.
28. Niksanen A., Saramaki M. & Shwandt E. (2006) Myeloperoxidase (MPO) and hs-CRP as predict factors for myocardial infarction. Clinical Laboratory International 18, 38-39.
29. Podrez E.A., Abu-Soud A.M. & Hazen S.L. (2000) Myeloperoxidase - generated oxidants and atherosclerosis. Free Radical Biology and Medicine 28, 1717-1725.
30. Podrez E.A., Febbraio M., Sheibani N., Schmitt D., Silverstein R.L., Hajjar D.P., Cohen P.A, Frazier W.A., Hoff H. F. & Hazen S.L. (2000) Macrophages scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. Journal of Clinical Investigation 105, 1095-1108.
31. Rader D.J. (2000) Inflammatory markers of coronary risk. The New England Journal of Medicine 343, 1179-1182.
32. Ridker P.M. (2003) Clinical application of C-reactive protein for cardiovascular discare detection and prevention. Circulation 107, 363-369.
33. Ridker P.M., Stampfer M.J. & Rifai N. (2001) Novel risk factor for systemic atherosclerosis a comparison of Creactive protein, fibrinogen, homocysteinc, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA: The Journal of the American Medical Association 285, 2481-2485.
34. Ross R. (1999) Atherosclerosis- on inflammatory disease. The New England Journal of Medicine 340, 115-126.
35. Vita J.A., Bernnan M.L., Gokce N., Mann S.A., Goormastic M., Shishehbor M.H., Penn M.S., Keaney J.F. & Hazen S. (2004) Serum myeloperoxidase level independently predicts endothelial dysfunction in humans. Circulation 110, 1134-1139.